Patents by Inventor Markus Furegati

Markus Furegati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic compounds and their uses
    Patent number: 11878973
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 23, 2024
    Assignee: NOVARTIS AG
    Inventors: Vincent Bordas, Jvan Brun, Markus Furegati, Jacques Hamon, Jürgen Hans-Hermann Hinrichs, Philipp Holzer, Fatma Limam, Henrik Möbitz, Sandro Nocito, Simone Plattner, Niko Schmiedeberg, Joseph Schoepfer, Ross Sinclair Strang, Frédéric Zecri
  • Bicyclic Compounds and their Uses
    Publication number: 20230046859
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Application
    Filed: May 25, 2022
    Publication date: February 16, 2023
    Inventors: Vincent BORDAS, Jvan BRUN, Andrea DECKER, Markus FUREGATI, Geoffrey GOGNIAT, Wanben GONG, Jacques HAMON, Jürgen Hans-Hermann HINRICHS, Philipp HOLZER, Fatma LIMAM, Henrik MÖBITZ, Sandro NOCITO, Simone PLATTNER, Niko SCHMIEDEBERG, Joseph SCHOEPFER, Jessica SOTO, Ross Sinclair STRANG, Shuping YAO, Huangchao YU, Frédéric ZECRI, Sisi ZHANG
  • Beta-lactamase inhibitors
    Patent number: 10597396
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20190177324
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Application
    Filed: September 28, 2017
    Publication date: June 13, 2019
    Applicant: Novartis AG
    Inventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
  • Beta-lactamase inhibitors
    Patent number: 10065957
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20180086762
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 29, 2018
    Inventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
  • Novel Crystalline Forms of Entacapone and Production Thereof
    Publication number: 20080076825
    Abstract: The invention relates to three novel forms of entacapone. These are peripheral and selective COMT inhibitors which in combination with levodopa and decarboxylase inhibitors can be used to treating Parkinson's syndrome. Said novel forms arise by crystallization of entacapone in respectively determined conditions. In certain cases, entacapone can be used as a raw product, in a special case it can be used in situ as the product of Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide. Also disclosed are improvements of said condensation in relation to the catalyst and the production of the two components thereof.
    Type: Application
    Filed: December 27, 2004
    Publication date: March 27, 2008
    Inventors: Thomas Bader, Markus Furegati, Oliver Jungmann